DJIA 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%

3.05 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

PSTI $3.05 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.05
Previous Close $3.05
Daily Range $3.00 - $3.06
52-Week Range $2.26 - $5.00
Market Cap $178.8M
P/E Ratio -8.47
Dividend (Yield) $0.00 (0.0%)
Volume 116,712
Average Daily Volume 135,679
Current FY EPS -$0.37

Sector

Healthcare

Industry

Drugs

PLURISTEM THERAPEUTICS, INC. (PSTI) Description

Pluristem Therapeutic is a bio-therapeutics Company dedicated to the commercialization of non-personalized cell therapy products for the treatment of several severe degenerative ischemic and autoimmune disorders. Website: http://www.pluristem.com/

News & Commentary

Pluristem Gets FDA's Orphan Drug Nod for Anemia Treatment

Seven-year window of exclusivity, tax credits among benefits upon drug approval.

A Peek Into The Market Before The Trading Starts

Pluristem Announces First Clinical Indication for PLX-RAD Cells for Use in Hematology

United Therapeutics' Second PAH Stumble Emphasizes The Need For Pluristem's Therapy

PSTI Plans to Start Phase I Study - Analyst Blog

Investing In The Stem Cell Sector: An Overview

UTHR to Move PAH Drug into Phase I - Analyst Blog

United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Ce

United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy

Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy

Pipeline Progress at Pluristem - Analyst Blog

Pipeline Progress at Pluristem - Analyst Blog

See More PSTI News...

PSTI's Top Competitors

PSTI $3.05 (0.00%)
Current stock: PSTI
AMGN $105.63 (0.63%)
Current stock: AMGN
GILD $56.30 (2.44%)
Current stock: GILD
BIIB $226.85 (-0.50%)
Current stock: BIIB